The Pfizer-BioNTech vaccine use mRNA to generate antibodies. Photo: Reuters
Coronavirus mutations pose challenge to vaccine makers
- Studies send mixed messages whether the Pfizer-BioNTech vaccine will be able to tackle the variant that emerged in Britain
- New strains of the virus add to challenge of fighting Covid-19
Follow your favourite topic and get notified
The Pfizer-BioNTech vaccine use mRNA to generate antibodies. Photo: Reuters